Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Nitroglycerin ointment for the prevention of postmenopausal osteoporosis.

Beckett RD, Sheehan AH.

Ann Pharmacother. 2011 Dec;45(12):1566-70. doi: 10.1345/aph.1Q410. Epub 2011 Oct 18. Review.

PMID:
22009995
2.

Strontium ranelate for the management of osteoporosis.

Lam S, Zouzias K.

Consult Pharm. 2008 Jul;23(7):531-7.

PMID:
18764671
3.

Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.

Sutton EE, Riche DM.

Ann Pharmacother. 2012 Jul-Aug;46(7-8):1000-9. doi: 10.1345/aph.1Q543. Epub 2012 Jul 25. Review.

PMID:
22837347
5.

Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.

Woodis CB.

Ann Pharmacother. 2008 Jul;42(7):1085-9. doi: 10.1345/aph.1K652. Epub 2008 May 27.

PMID:
18505912
6.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
7.

Natural health products in the prevention and treatment of osteoporosis: systematic review of randomized controlled trials.

Whelan AM, Jurgens TM, Bowles SK.

Ann Pharmacother. 2006 May;40(5):836-49. Epub 2006 May 2. Review.

PMID:
16670364
8.

[Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].

Reginster JY.

J Gynecol Obstet Biol Reprod (Paris). 2002 Oct;31(6):541-9. Review. French.

9.
10.

Risedronate: a clinical review.

Crandall C.

Arch Intern Med. 2001 Feb 12;161(3):353-60. Review.

PMID:
11176760
11.

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.

Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD; Bazedoxifene Study Group.

Osteoporos Int. 2012 Jan;23(1):351-63. doi: 10.1007/s00198-011-1691-1. Epub 2011 Jul 21.

PMID:
21779819
12.

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.

Jolly EE, Bjarnason NH, Neven P, Plouffe L Jr, Johnston CC Jr, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW.

Menopause. 2003 Jul-Aug;10(4):337-44.

PMID:
12851517
13.
14.

Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.

Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.

Chin Med J (Engl). 2004 Jul;117(7):1029-35.

PMID:
15265377
15.

Teriparatide for severe osteoporosis.

Cappuzzo KA, Delafuente JC.

Ann Pharmacother. 2004 Feb;38(2):294-302. Epub 2003 Dec 30. Review.

PMID:
14742769
16.

Bazedoxifene: bazedoxifene acetate, TSE 424, TSE-424, WAY 140424.

[No authors listed]

Drugs R D. 2008;9(3):191-6.

PMID:
18457472
17.

Osteodensitometry in healthy postmenopausal women.

[No authors listed]

Prescrire Int. 2008 Apr;17(94):68-72.

PMID:
18536138
18.

Should postmenopausal hormone therapy be used to prevent osteoporosis?

Sicat BL.

Consult Pharm. 2004 Aug;19(8):725-35.

PMID:
16553495
19.

Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.

Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.

Bone. 2006 Dec;39(6):1268-75. Epub 2006 Aug 1.

PMID:
16884968
20.

Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.

Palacios S.

Curr Med Res Opin. 2010 Jul;26(7):1553-63. doi: 10.1185/03007991003795873. Review.

PMID:
20429824

Supplemental Content

Support Center